New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLeuprolide vs Larazotide Acetate

Leuprolide vs Larazotide Acetate

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
Leuprolide
Recovery & Repair
Larazotide Acetate
Summary
Leuprolide is a synthetic GnRH superagonist that, with continuous administration, paradoxically suppresses LH and FSH through receptor desensitization — the opposite effect of pulsatile GnRH. Used medically for prostate cancer, endometriosis, and precocious puberty. In men's health, short-duration use for PCT and testosterone suppression rebound.
Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
Half-Life
~3 hours (SC/IM), but depot formulations last 1–12 months
Local gut action; minimal systemic exposure
Admin Route
SubQ, IM
Oral
Research
Typical Dose
7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
0.5-2 mg
Frequency
Per depot schedule
3x daily
Key Benefits
  • Medical: reduces testosterone in prostate cancer
  • Medical: suppresses estrogen in endometriosis and uterine fibroids
  • Medical: delays precocious puberty
  • Research: testosterone rebound effect after short course
  • Transgender care: hormone suppression in adolescents
  • Research: hormonal re-sensitization protocols
  • Directly reduces intestinal tight junction permeability
  • Clinical efficacy in celiac disease (Phase 3 trials)
  • Reduces systemic inflammation from gut permeability
  • Targets root cause of leaky gut (Zonulin pathway)
  • Local gut action without systemic absorption
  • Potential application in IBS, IBD, autoimmune conditions
Side Effects
  • Hot flashes (with testosterone suppression)
  • Decreased libido and erectile dysfunction
  • Initial testosterone flare (first 1–2 weeks)
  • Bone density loss with long-term use
  • +3 more
  • Headache (mild, dose-dependent)
  • Nausea (rare)
  • Well-tolerated overall in clinical trials
Stacks With